Armistice Capital, LLC Altimmune, Inc. Transaction History

Armistice Capital, LLC

  • $6.02 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$9.85 - $16.46 $5.28 Million - $8.82 Million
-536,000 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$12.71 - $24.31 $6.81 Million - $13 Million
536,000 New
536,000 $7.57 Million
Q4 2020

Feb 16, 2021
SELL
$7.84 - $14.22 $11.3 Million - $20.4 Million
-1,436,000 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$9.93 - $33.26 $14.3 Million - $47.8 Million
1,436,000 New
1,436,000 $19 Million

Others Institutions Holding ALT

# of Institutions
183
Shares Held
38.9M
Call Options Held
873K
Put Options Held
695K
View Full List

About Altimmune, Inc.

ALT Quotes by TradingView
  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $415M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email